您的位置:主页会员风采会员企业副理事长单位
深圳华大智造科技有限公司
发布日期:2018-05-17 13:53     浏览次数:     来源:基因产学研资联盟
深圳华大智造科技有限公司(简称华大智造)是华大基因集团下属子公司,秉承“基因科技造福人类”的理念,致力于基因科技的创新,专注于生命科学与医疗健康领域仪器设备、试剂耗材等相关产品的研发、制造、生产和销售,提供实时、全景、全生命周期的生命数字化全套设备,为精准医疗、精准农业和精准健康等关系国计民生的实际需求提供自主可控的先进设备、技术保障和解决方案。
2013年3月,成功收购美国上市公司Complete Genomics,实现了基因测序上下游产业链的闭环;2014年,整合并开发了自主可控的核心测序技术,实现了基因测序仪的国产化研发;2015年,正式推出了具备国际先进水平的桌面型高通量基因测序仪BGISEQ-500系列产品并于2016年10月获得国家食品药品监督管理总局医疗器械注册证;同年11月,正式推出新款高通量台式测序仪BGISEQ-50。
2017年10月,在刚刚结束的第十二届国际基因组学大会(ICG-12),华大智造重磅新品再次引发业内关注,包括两款全新的台式基因测序仪MGISEQ-200和MGISEQ-2000,以及一步整合测序全流程的NGS工作站MGIFLP、远程超声诊断系统MGIUS-R3等系列产品。
 
MGI is committed to the innovation of trans-omics, focused on the R&D, manufacture, and distribution of genomics research equipment & reagents, In Vitro Diagnostic equipment & reagents, and medical devices. Its mission is to provide comprehensive and transformative genomics solutions for the advancement of Precision Medicine, Agrigenomics, and Personalized Healthcare.
In March 2013, MGI acquired Complete Genomics, a leader in accurate human whole genome sequencing. In 2014, the self-controllable core sequencing technology was integrated and developed by MGI, and the localization of sequencers was realized successfully. In 2015, MGI launched BGISEQ-500, a benchtop high-throughput open sequencing platform that provides end-to-end solutions, and then the China Food and Drug Administration (CFDA) approved the registration. In 2016, MGI launched BGISEQ-50, a desktop high-throughput sequencing platform that aims to be sharp and be smart. In 2017, at the 12th International Conference on Genomics (ICG-12) in Shenzhen, MGI announced three new sequencing systems——MGISEQ-2000 and MGISEQ-200, which have improved performance over the existing BGISEQ-500 and BGISEQ-50, and MGIFLP, an automated system that integrates sample prep and sequencing. In addition, MGI is branching out into developing healthcare instrumentation for areas outside of molecular diagnostics, announcing a robotic ultrasound system, MGIUS-R3, that it plans to commercialize for prenatal and infectious disease diagnostics in remote areas.

0